Abstract
Background/Aims
Hepatocellular carcinoma (HCC) is a unique condition where the cause of
death might not only be due to progressive cancer, but also from liver failure. We evaluated
specific causes of death for HCC patients who were initially diagnosed within the Milan criteria.
Methods
A retrospective cohort of 147 patients with mortality who were initially diagnosed
with HCC within the Milan criteria between January 2008 and December 2012 at a single
institution was reviewed.
Results
During follow-up, 104 patients (70.7%) experienced one or more cirrhotic complications,
such as ascites, variceal bleeding, or hepatic encephalopathy. Near mortality, cancer progression
(exceeding the Milan criteria) was recorded for 102 patients (69.3%), while cirrhosis progression
(greater than two-point increase in Child-Pugh score) was noted in 110 (74.8%) patients. Alphafetoprotein,
protein-induced by vitamin K antagonist-II levels and treatment modality were
associated with cancer progression, while age and Child-Pugh class were associated with
cirrhosis progression. There were 61 patients with in-hospital mortality; cancer progression
plus liver failure was noted in 34 patients (55.7%), liver failure without cancer progression was
seen in 20 patients (32.8%), and only four patients (6.6%) showed mortality from extrahepatic
metastasis without liver failure.
Conclusions
Among HCC patients who were diagnosed within the Milan criteria, most of them
had cirrhosis progression near mortality, and significant proportion died without uncontrolled
cancer growth, mainly due to liver failure. These findings show the importance of liver function
that should be considered in managing HCC patients.
Citations
Citations to this article as recorded by
- 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Journal of Liver Cancer.2023; 23(1): 1. CrossRef - Clinical Outcomes of Hepatitis B Virus–Related Hepatocellular Carcinoma Patients with Undetectable Serum HBV DNA Levels
Jong-In Chang, Dong Hyun Sinn, Hyun Cho, Seonwoo Kim, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik
Digestive Diseases and Sciences.2022; 67(9): 4565. CrossRef - 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Clinical and Molecular Hepatology.2022; 28(4): 583. CrossRef - 2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma
Korean Journal of Radiology.2022; 23(12): 1126. CrossRef - Stereotactic Ablative Radiotherapy for Oligometastatic Hepatocellular Carcinoma: A Multi-Institutional Retrospective Study (KROG 20-04)
Tae Hyung Kim, Taek-Keun Nam, Sang Min Yoon, Tae Hyun Kim, Young Min Choi, Jinsil Seong
Cancers.2022; 14(23): 5848. CrossRef - Multidisciplinary approach is associated with improved survival of hepatocellular carcinoma patients
Dong Hyun Sinn, Gyu-Seong Choi, Hee Chul Park, Jong Man Kim, Honsoul Kim, Kyoung Doo Song, Tae Wook Kang, Min Woo Lee, Hyunchul Rhim, Dongho Hyun, Sung Ki Cho, Sung Wook Shin, Woo Kyoung Jeong, Seong Hyun Kim, Jeong Il Yu, Sang Yun Ha, Su Jin Lee, Ho Yeon
PLOS ONE.2019; 14(1): e0210730. CrossRef - Hepatocellular carcinoma with extrahepatic metastasis: Are there still candidates for transarterial chemoembolization as an initial treatment?
Jihye Kim, Dong-Hyun Sinn, Moon Seok Choi, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Enzo Tagliazucchi
PLOS ONE.2019; 14(3): e0213547. CrossRef